Business Of Biotech

Plant-Based Biologics With iBio's Randy Maddux

February 14, 2022 Matt Pillar
Plant-Based Biologics With iBio's Randy Maddux
Business Of Biotech
More Info
Business Of Biotech
Plant-Based Biologics With iBio's Randy Maddux
Feb 14, 2022
Matt Pillar

We love to hear from our listeners. Send us a message.

iBio COO Randy Maddux walks us through the Bryan, Texas-based biopharma's attempt to turn the CHO cell biologic development paradigm on its ear with hydroponically-grown N. benthamiana. His company's FastPharming approach to protein production, he says, could be modularized to speed cycle times and dramatically reduce upstream costs at scales large and small.  For its part, iBio is proving out the approach on a host of therapeutic and vaccine candidates for oncological, infectious, and fibrotic diseases.

Learn more about iBio's COVID-19 vaccine candidate from CEO Tom Isett and Head of Vaccine Development Melissa Berquist, Ph.D.  in this feature story at bioprocessonline.com.

You've listened along for years -- now you can watch along, too! Go to bioprocessonline.com/solution/the-business-of-biotech-podcast, where you can put faces to voices as you watch hundreds of interviews with the world's best biotech builders. While you're there, subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!

Show Notes

We love to hear from our listeners. Send us a message.

iBio COO Randy Maddux walks us through the Bryan, Texas-based biopharma's attempt to turn the CHO cell biologic development paradigm on its ear with hydroponically-grown N. benthamiana. His company's FastPharming approach to protein production, he says, could be modularized to speed cycle times and dramatically reduce upstream costs at scales large and small.  For its part, iBio is proving out the approach on a host of therapeutic and vaccine candidates for oncological, infectious, and fibrotic diseases.

Learn more about iBio's COVID-19 vaccine candidate from CEO Tom Isett and Head of Vaccine Development Melissa Berquist, Ph.D.  in this feature story at bioprocessonline.com.

You've listened along for years -- now you can watch along, too! Go to bioprocessonline.com/solution/the-business-of-biotech-podcast, where you can put faces to voices as you watch hundreds of interviews with the world's best biotech builders. While you're there, subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!

Podcasts we love